发明授权
- 专利标题： TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
-
申请号： US16386886申请日： 2019-04-17
-
公开(公告)号： US10933077B2公开(公告)日： 2021-03-02
- 发明人: Peter Wipf , Matthew D. Neal , Chhinder P. Sodhi , David J. Hackam
- 申请人： UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 申请人地址： US PA Pittsburgh
- 专利权人： UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 当前专利权人： UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 当前专利权人地址： US PA Pittsburgh
- 代理机构： Baker Botts L.L.P.
- 主分类号： A01N43/04
- IPC分类号： A01N43/04 ; A61K31/70 ; A61K31/7028 ; A61K31/7008 ; A61K31/7034 ; A61K31/7024 ; A61K31/351
摘要：
The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
信息查询
IPC分类:
